In summary, our data are consistent with a model in which a poorly immunogenic tumor is partially sensitive to ICI therapy through the selective re-invigoration/expansion of anti-tumor CD8+ T cell populations presumably recognizing weak, sub-dominant antigens. Here, CD8A is linked to neoplasm.